Abbott India: Sustainable Performance Gaining Market Share
We expect Revenue/PAT CAGR of 11.1%/11.3% respectively over FY21-FY24E. While a TP of Rs 20,000 implies a marginal downside of 2.5%, we remain...
463 Views
Abbott India: Sales Improvement in Key Therapies
We expect stable sales in the Duphaston brand and an increase in volume in the Thyronorm brand to result in revenue and PAT CAGR of 11.1% and 11.3%...
261 Views